About: COVID-19 in persons with chronic myeloid leukaemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in persons with chronic myeloid leukaemia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 in persons with chronic myeloid leukaemia
Creator	Qin, Jun Li, Qing Chen, • Li, • Robert, • Cheng, • You, Yong Chang, Wei Yuan, Guolin Association, Anti-Cancer Chen, Shiming Chucheng, • Gale, Peter Guo, Jingming Hubei, • Jiang, • Li, Weiming Lingshuang Sheng, • Wang, Danyu Xiaojian, • Yang, Zhuangzhi Zhang, Youshan
Source	Medline; PMC
abstract	We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1038/s41375-020-0853-6
bibo:pmid	32424293
has license	no-cc
sha1sum (hex)	d475336d848745c93d6e36fb30418aba2bf67954
schema:url	https://doi.org/10.1038/s41375-020-0853-6
resource representing a document's title	COVID-19 in persons with chronic myeloid leukaemia
has PubMed Central identifier	PMC7233329
has PubMed identifier	32424293
schema:publication	Leukemia
resource representing a document's body	covid:d475336d848745c93d6e36fb30418aba2bf67954#body_text
is schema:about of	named entity 'COVID-19' named entity 'infected' named entity 'SARS-CoV-2' named entity 'Confidence Interval' named entity 'PROBABLE' named entity '0.1' named entity 'NORMAL' named entity 'HUBEI PROVINCE' named entity 'SARS-COV-2' named entity '2ND' named entity '096' named entity 'PROVIDERS' named entity 'COMPLETE' covid:arg/d475336d848745c93d6e36fb30418aba2bf67954 named entity 'Hubei Province' named entity 'health-care' named entity 'Other' named entity 'Persons' named entity 'phase' named entity 'COVID-19' named entity 'subjects' named entity 'subjects' named entity 'higher' named entity 'risk factors' named entity 'questionnaire' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'co-variates' named entity 'COVID-19' named entity 'infection' named entity 'COVID' named entity 'COVID-19' named entity 'COVID-19' named entity 'chronic myeloid leukaemia' named entity 'SARS-CoV-2' named entity 'fatigue' named entity 'SARS-CoV-2' named entity 'CT scan' named entity 'oxygen' named entity 'tyrosine' named entity 'Clinical features' named entity 'Union Hospital' named entity 'questionnaire' named entity 'co-morbidity' named entity 'haematologic' named entity 'Hubei Province' named entity 'CML' named entity 'CML' named entity 'SARS-CoV' named entity 'cough' named entity 'Pneumonia' named entity 'lung' named entity 'RT-PCR' named entity 'CML' named entity 'COVID-19' named entity 'CT scan' named entity 'clinical features' named entity 'co-variates' named entity 'ponatinib' named entity 'SPSS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software